Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.
Clinical studies have shown that NST has better therapeutic results with chronic myelogenous leukemia (CML) than acute leukemia (AL), but whether the generation of graft-versus-leukemia (GVL) effects is different between AL and CML patients early after NST has not yet been studied, so we used a pentamer-staining technique in combination with ICCS to detect WT1(+)CD8(+)CTL/WT1(+)Tc1 and WT1(+)Th1 cells in these two groups of patients. Results showed that the emergence time of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 cells after NST in AL patients was similar to that in CML patients (P = 0.58), while the emergence time of WT1(+)Th1 cells after NST in AL patients was shorter than in CML patients (P = 0.047). Furthermore, the peak proportions of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 (P > 0.05) and WT1(+)Th1 (P > 0.05) cells were similar between AL and CML patients, and the increased rates (P > 0.05) and elevated levels (P > 0.05) of WT1-specific T cells were not statistically different between the groups after G-CSF mobilized donor mononuclear cell infusion. In addition, the reconstruction of lymphocyte subsets (P > 0.05) and CD4/8 ratios (P > 0.05) in AL patients were not statistically different from those in CML patients within 180 days after NST. These results suggested that WT1 maybe induces similar GVL effects in both AL and CML patients early after NST.
Wei
Li
L
Department of Hematology, Affiliated Hospital of Academy of Military Medicine Science, Beijing, China. weili75114cn2001@yahoo.com.cn
Zuo
HongLi
H
Sun
XueDong
X
Liu
TieQiang
T
Guo
Mei
M
Liu
GuangXian
G
Sun
QiYun
Q
Qiao
JianHui
J
Wang
DanHong
D
Yu
ChangLin
C
Hu
KaiXun
K
Dong
Zheng
Z
Ai
HuiSheng
H
D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D002648:Child; D005260:Female; D005434:Flow Cytometry; D015973:Gene Expression Regulation, Leukemic; D020544:Graft vs Leukemia Effect / Q000502:physiology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000378:metabolism* / Q000473:pathology; D018417:Th1 Cells / Q000378:metabolism / Q000473:pathology; D018183:Transplantation Chimera; D014184:Transplantation, Homologous; D025721:WT1 Proteins / Q000235:genetics / Q000378:metabolism*; D055815:Young Adult
D019653:Myeloablative Agonists; D025721:WT1 Proteins